NCT 03185364.
| Trial name or title | The safety and efficiency of sildenafil in the treatment of severe post‐capillary pulmonary hypertension caused by COPD |
| Methods | Randomised, double‐blind, parallel, placebo‐controlled trial |
| Participants | Aged 40 to 85 years with COPD and PH (mean PAP ≥ 35 mmHg, PAWP ≤ 15 mmHg) |
| Interventions | Sildenafil 20 mg t3 times daily |
| Outcomes |
Measured at 12 weeks |
| Starting date | June 14, 2017 |
| Contact information | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China, 430030 |
| Notes | ClinicalTrials.gov Identifier: NCT03185364 Currently recruiting |